MedTrace Logo

Neurocognitive Effects of Buprenorphine Among HIV+ and HIV-Opioid Users

NCT01108679 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2019-04-10

No results posted yet for this study

Summary

The purpose of this study is to examine how Buprenorphine, a form of opioid addiction treatment, changes the ability to think and reason among people addicted to opiates, who are either HIV negative or HIV positive. In addition, blood samples will be stored for HIV+ and HIV- individuals who take buprenorphine to study its effect. This study hypothesizes that the HIV positive participants will demonstrate significant improvement in thinking and reasoning ability at 3 and 6 months compared to baseline, but that their thinking and reasoning ability will still be lower than HIV negative participants. This study also hypothesizes the biomarkers in participants' blood samples will be associated with measures of change in thinking and reasoning ability.

Conditions

  • Opioid-related Disorders
  • Buprenorphine
  • HIV
  • Cognition
  • HIV Infections

Sponsors & Collaborators

  • Montefiore Medical Center

    collaborator OTHER

  • Fordham University

    collaborator OTHER

  • Albert Einstein College of Medicine

    lead OTHER

Principal Investigators

  • Julia Arnsten, M.D., M.P.H. · Albert Einstein College of Medicine

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-12-01
Primary Completion
2012-02-01
Completion
2012-02-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01108679 on ClinicalTrials.gov